Figure 1

![Figure 1: Clinical cohort characteristics and study design for the multiomics analysis of 278 Crohn's disease patients and 28 healthy controls are outlined, establishing the framework for identifying microbial metabolite signatures linked to intestinal fibrosis.]()

> Source: Xuehua Li et al. "Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in." *EMBO molecular medicine*, 2024. PMID: [39271960](https://pubmed.ncbi.nlm.nih.gov/39271960/)

<figure>
  <img src="" alt="Clinical cohort characteristics and study design for the multiomics analysis of 278 Crohn's disease patients and 28 healthy controls are outlined, establishing the framework for identifying microbial metabolite signatures linked to intestinal fibrosis." />
  <figcaption>Figure 1. Clinical cohort characteristics and study design for the multiomics analysis of 278 Crohn's disease patients and 28 healthy controls are outlined, establishing the framework for identifying microbial metabolite signatures linked to intestinal fibrosis.<br>  Source: Xuehua Li et al. "Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in." <em>EMBO molecular medicine</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39271960/">39271960</a></figcaption>
</figure>